JP2017517520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017517520A5 JP2017517520A5 JP2016569847A JP2016569847A JP2017517520A5 JP 2017517520 A5 JP2017517520 A5 JP 2017517520A5 JP 2016569847 A JP2016569847 A JP 2016569847A JP 2016569847 A JP2016569847 A JP 2016569847A JP 2017517520 A5 JP2017517520 A5 JP 2017517520A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- patient
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004298P | 2014-05-29 | 2014-05-29 | |
| US62/004,298 | 2014-05-29 | ||
| PCT/US2015/032351 WO2015183776A1 (en) | 2014-05-29 | 2015-05-26 | Methods for treating cancer with a wee1 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019232432A Division JP2020073520A (ja) | 2014-05-29 | 2019-12-24 | Ｗｅｅ１阻害剤を用いた癌を処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017517520A JP2017517520A (ja) | 2017-06-29 |
| JP2017517520A5 true JP2017517520A5 (enExample) | 2018-06-28 |
Family
ID=54699632
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569847A Pending JP2017517520A (ja) | 2014-05-29 | 2015-05-26 | Ｗｅｅ１阻害剤を用いた癌を処置する方法 |
| JP2019232432A Pending JP2020073520A (ja) | 2014-05-29 | 2019-12-24 | Ｗｅｅ１阻害剤を用いた癌を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019232432A Pending JP2020073520A (ja) | 2014-05-29 | 2019-12-24 | Ｗｅｅ１阻害剤を用いた癌を処置する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20170095479A1 (enExample) |
| EP (1) | EP3148544A4 (enExample) |
| JP (2) | JP2017517520A (enExample) |
| WO (1) | WO2015183776A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170095479A1 (en) * | 2014-05-29 | 2017-04-06 | Merck Sharp & Dohme Corp. | Methods for Treating Cancer with a WEE1 Inhibitor |
| WO2019134070A1 (en) * | 2018-01-02 | 2019-07-11 | Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine | Panda as novel therapeutic |
| PE20211475A1 (es) | 2018-12-20 | 2021-08-05 | Amgen Inc | Inhibidores de kif18a |
| JP7631348B2 (ja) * | 2019-12-20 | 2025-02-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 組み合わせ |
| TW202203919A (zh) * | 2020-04-14 | 2022-02-01 | 美商安進公司 | 用於治療贅生性疾病之ｋｉｆ１８ａ抑制劑 |
| US12522607B2 (en) | 2020-06-17 | 2026-01-13 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Substituted pyrazolo[3,4-d]pyrimidines as wee-1 inhibitors |
| CA3183025A1 (en) * | 2020-06-24 | 2021-12-30 | Melissa Dumble | Companion diagnostic tool for mutant p53 reactivating compounds |
| WO2023028564A1 (en) | 2021-08-26 | 2023-03-02 | Volastra Therapeutics, Inc. | Spiro indoline inhibitors of kif18a |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2689429C (en) * | 2007-06-15 | 2012-08-21 | Banyu Pharmaceutical Co., Ltd. | Bicycloaniline derivatives |
| WO2011027800A1 (en) * | 2009-09-02 | 2011-03-10 | Banyu Pharmaceutical Co.,Ltd. | Use of biomarker(s) to identify a wee1 inhibitor responsive patient and methods of treating cancer mediated by dysfunctional or aberrant p53 via administration of a wee1 inhibitor |
| TW201304778A (zh) * | 2010-11-16 | 2013-02-01 | Array Biopharma Inc | 檢查點激酶１抑制劑及ｗｅｅ１激酶抑制劑之組合 |
| US9506926B2 (en) * | 2011-02-18 | 2016-11-29 | The Regents Of The University Of California | Molecular predictors of therapeutic response to specific anti-cancer agents |
| EP2755482B1 (en) * | 2011-09-15 | 2016-06-01 | Merck Sharp & Dohme Corp. | Combination of mk-1775 and mk-8776 for treating cancer |
| US20170095479A1 (en) * | 2014-05-29 | 2017-04-06 | Merck Sharp & Dohme Corp. | Methods for Treating Cancer with a WEE1 Inhibitor |
-
2015
- 2015-05-26 US US15/314,650 patent/US20170095479A1/en not_active Abandoned
- 2015-05-26 JP JP2016569847A patent/JP2017517520A/ja active Pending
- 2015-05-26 WO PCT/US2015/032351 patent/WO2015183776A1/en not_active Ceased
- 2015-05-26 EP EP15800163.6A patent/EP3148544A4/en not_active Ceased
-
2019
- 2019-12-06 US US16/705,592 patent/US11364243B2/en active Active
- 2019-12-24 JP JP2019232432A patent/JP2020073520A/ja active Pending
-
2022
- 2022-05-23 US US17/664,476 patent/US20230083689A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521194A5 (enExample) | ||
| JP2016525097A5 (enExample) | ||
| PE20170312A1 (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso | |
| JP2021526132A5 (enExample) | ||
| JP2015533176A5 (enExample) | ||
| JP2016533366A5 (enExample) | ||
| MX384828B (es) | Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. | |
| FI3618875T3 (fi) | Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito | |
| JP2018507249A5 (enExample) | ||
| NZ602385A (en) | Methods of treating cancer | |
| MX2015011752A (es) | Metodos para tratar cancer de pulmon. | |
| PH12015502046A1 (en) | Pyridinyl and fused pyridinyl triazolone derivatives | |
| JP2015536950A5 (enExample) | ||
| PH12016502354A1 (en) | Pharmaceutical composition | |
| NZ732154A (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| JP2017528475A5 (enExample) | ||
| WO2014180889A8 (en) | Methods and compositions for the treatment of cancer | |
| PH12016502249A1 (en) | Pladienolide pyridine compounds and methods of use | |
| JP2015512398A5 (enExample) | ||
| JP2017527582A5 (enExample) | ||
| WO2013112950A3 (en) | Certain chemical entities, compositions, and methods | |
| MX2016000131A (es) | Nanoparticulas polimericas de docetaxel para el tratamiento de cancer. | |
| JP2017535601A5 (enExample) | ||
| WO2016127168A3 (en) | Mebendazole polymorph for treatment and prevention of tumors | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения |